AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29097122
Drug: FT+9000 gel
RxNorm normalized name: lactase 9000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT+9000 gel
Trial: 22356267
Drug: Selenomethionine (Seme)
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenomethionine (Seme) 200μg daily for 3 months (Se3), n = 15
Trial: 22356267
Drug: Selenomethionine (Seme)
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenomethionine (Seme) 200μg daily for 6 months (Se6), n = 46
Trial: 17875253
Drug: Healthy Children,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Children, Strong Families intervention promoting healthy eating and physical activity; details on dosage and duration not specified.
Trial: 11553197
Drug: Nasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal insulin (three preprandial doses combined with one evening subcutaneous NPH if needed)
Trial: 11553197
Drug: NPH injections
RxNorm normalized name: INSULIN,NPH,BEEF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH injections (two daily)
Trial: 7989953
Drug: Single-dose NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose NSAIDs
Trial: 7989953
Drug: Low- and
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low- and high-dose NSAIDs
Trial: 7989953
Drug: Recommended and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended and supramaximal single doses of three NSAIDs
Trial: 7989953
Drug: Weak opioids
RxNorm normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weak opioids (WO) alone or in combination (WO/C) with nonopioid analgesics
Trial: 7989953
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of WO/C analgesics
Trial: 7989953
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of NSAIDs
Trial: 3171371
Drug: Prilocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 3% with felypressin 0.03 international units/ml
Trial: 24724835
Drug: Topical benzocaine
RxNorm normalized name: benzocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzocaine
Trial: 22744627
Drug: Metformin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin administration
Trial: 17461735
Drug: Non-antiarrhythmic drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antiarrhythmic drugs (beta-blockers, aldosterone antagonists, ACE inhibitors, angiotensin receptor-blockers, statins, omega-3 fatty acids)
Trial: 17461735
Drug: Non-antiarrhythmic drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antiarrhythmic drugs
Trial: 10378327
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of proximal deep vein thrombosis or symptomatic pulmonary embolism and permanent/unknown triggering factor
Trial: 10378327
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of cardiolipin antibodies
Trial: 6133575
Drug: Aversion-relief therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aversion-relief therapy
Trial: 30113559
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral cochlear implantation with a 2‐year interimplant interval
Trial: 26955768
Drug: Succinylcholine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine administration during rapid sequence induction (RSI) for general anesthesia
Trial: 22248711
Drug: Pegfilgrastim (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (single subcutaneous injection at day 5)
Trial: 22248711
Drug: Filgrastim (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (daily injections from day 5 until recovery of ANC to 0.5 G/L)
Trial: 19439949
Drug: Conventional dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional dentifrice (1,100 microg F/g)
Trial: 19439949
Drug: Low-F dentifrice
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-F dentifrice (500 microg F/g)
Trial: 17617747
Drug: Ranolazine 750
RxNorm normalized name: Ranolazine 750 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine 750 mg or 1000 mg bid
Trial: 11205198
Drug: 5-fluorouracil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (5 FU) alone (arm A: 450 mg/m2/day‐5/21 days)
Trial: 11205198
Drug: Combined folinic
RxNorm normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined folinic acid (FOL) and 5 FU (arm B: 200 mg/m2 racemic form or 100 mg/m2‐l‐form and 370 mg/m2/day‐5/21 days)
Trial: 9315984
Drug: Phenytoin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (200 mg a.m. and 100 mg p.m.)
Trial: 3948628
Drug: Octylonium bromide
RxNorm normalized name: octylonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octylonium bromide (80 mg, qid, per os) for 5-7 days
Trial: 3948628
Drug: IBS patients
RxNorm normalized name: Ibsrela
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IBS patients (without treatment)
Trial: 31132664
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 20 mg/mL once daily (GA20)
Trial: 21253774
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (individually adapted supplements enriched with protein and antioxidants)
Trial: 16507859
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) 81 mg once daily
Trial: 12735583
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue (5 mL delivered by aerosolized spraying)
Trial: 11054621
Drug: Carvedilol (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (long-term treatment, 4 months)
Trial: 11054621
Drug: Carvedilol (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (long-term treatment)
Trial: 9076868
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg T.I.D. for 48 hours
Trial: 9076868
Drug: Gabapentin higher
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin higher doses (up to 3600 mg/day) during open-label extension
Trial: 9076868
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg T.I.D. and 800 mg T.I.D.
Trial: 8398955
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch therapy
Trial: 8398955
Drug: Fentanyl as
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl as adjunct
Trial: 3533203
Drug: No blood
RxNorm normalized name: VivaGuard Ino Blood Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No blood transfusion unless hemoglobin fell below 8 g/dl or patients were shocked (control group)
Trial: 23686969
Drug: Cognitive–behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive–behavioral therapy
Trial: 17144124
Drug: Indomethacin (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (usual doses)
Trial: 10904510
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (12.5 mg/d of chlorthalidone, with possible addition of 25 mg/d of atenolol or 0.05 mg/d of reserpine)
Trial: 8439209
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g ampicillin-sulbactam (2 g ampicillin-1 g sulbactam), every 6 hours
Trial: 8439209
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin, every 6 hours
Trial: 3712636
Drug: Protamine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine (0.75 mg/kg/3 min)
Trial: 3712636
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (n = 8)
Trial: 18431480
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination with live attenuated yellow fever 17D vaccine at a reduced dose (1/5th; 0.1 mL)
Trial: 18431480
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination with live attenuated yellow fever 17D vaccine (0.5 mL)
Trial: 17205821
Drug: Resolving phlegm
RxNorm normalized name: Phleum pratense top
DrugBank: Phleum pratense top (DB14179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resolving phlegm method (RPM) using Chinese herbs (Indigo Naturalis 10 g, Alumen 3 g, Semen Cassiae 15 g, Fructus Crataegi 15 g, vinegar prepared Radix Bupleuri 10 g, Radix Curcumae 10 g, Radix Salviae Miltiorrhizae 12 g, Herba Lycopi 12 g, talc 12 g, Radix Glycyrrhizae 2 g), one dose twice per day orally for 12 weeks
Trial: 17205821
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid tablet (UAT) 150 mg three times per day for 12 weeks
Trial: 12557834
Drug: Alfentanil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 40 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Trial: 12557834
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Trial: 12557834
Drug: Remifentanil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 3 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Trial: 12557834
Drug: Remifentanil 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 4 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Trial: 8899093
Drug: Lansoprazole plus
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole plus amoxycillin (lansoprazole 30 mg o.m. for 6 or 8 weeks + amoxycillin 500 mg q.d.s. for the first 2 weeks)
Trial: 8899093
Drug: Lansoprazole alone
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole alone (30 mg o.m. for 6 or 8 weeks)
Trial: 1985415
Drug: High-dosage antioxidants
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage antioxidants (tocopherol and ascorbate)
Trial: 29228438
Drug: Low-dose dezocine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dezocine (0.05 mg/kg)
Trial: 29228438
Drug: Medium-dose dezocine
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose dezocine (0.1 mg/kg)
Trial: 29228438
Drug: High-dose dezocine
RxNorm normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose dezocine (0.15 mg/kg)
Trial: 29228438
Drug: Control (fentanyl:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (fentanyl: 10 μg/kg)
Trial: 25390761
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg daily (n = 18, 7 males)
Trial: 25390761
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg daily (n = 19, 3 males)
Trial: 14977896
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravaginal prostaglandin E(2) gel
Trial: 9081851
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg micronized form of fenofibrate
Trial: 29290275
Drug: Cold gel
RxNorm normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold gel pad application for 20 minutes in the postpartum first 2 hours and 4 hours after the first application
Trial: 29290275
Drug: Cold gel
RxNorm normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold gel pad application
Trial: 26317662
Drug: Regular Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Dose of Echinacea-Based Supplement (RD)
Trial: 26317662
Drug: Double Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Dose of Echinacea-Based Supplement (DD)
Trial: 24673056
Drug: Saturated-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saturated-dose group (30 cases) - heat-sensitive moxibustion until disappearance of heat-sensitive feeling, treated twice a day for 5 days, then once a day for 30 days.
Trial: 24673056
Drug: Traditional-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional-dose group (30 cases) - heat-sensitive moxibustion for 15 minutes each time, treated twice a day for 5 days, then once a day for 30 days.
Trial: 20725056
Drug: Atenolol with
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol with added diuretic (second-line therapy)
Trial: 20725056
Drug: Amlodipine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine with added perindopril (second-line therapy)
Trial: 18303278
Drug: Preventive measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive measures including fluoride varnish applications, mouthrinsing with 0.12% chlorhexine digluconate, professional oral hygiene.
Trial: 3621989
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine twice daily
Trial: 3621989
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg mefruside once daily
Trial: 3621989
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nifedipine and mefruside
Trial: 27217288
Drug: Very brief
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very brief intervention for promoting physical activity in primary care (details on dosage and duration not available)
Trial: 25385912
Drug: Gum-chewing (sugarless
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum-chewing (sugarless gum, 3 times daily for 30 min starting 6 hours postoperatively)
Trial: 22079797
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg docosahexaenoic acid (G-DHA) daily for 14 days
Trial: 22079797
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (G-OO) as placebo for 14 days
Trial: 10150489
Drug: Cistinexine dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cistinexine dihydrochloride (active drug)
Trial: 1988827
Drug: HA-1A (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1A (100 mg intravenous dose in 3.5 g of albumin)
Trial: 1988827
Drug: Placebo (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3.5 g of albumin)
Trial: 27400374
Drug: Celecoxib 800
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 800 mg/day for 14 days before surgery
Trial: 17233861
Drug: Rapid access
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid access to ultrasound and CA125 test for women with symptoms; no specific dosage or duration mentioned.
Trial: 12149108
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg three times a day for 8 weeks)
Trial: 9834911
Drug: Isoniazid plus
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid plus rifampin (300 mg isoniazid + 600 mg rifampin per day for 3 months)
Trial: 9834911
Drug: Isoniazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (300 mg per day for 9 months)
Trial: 7666798
Drug: Glutamine 0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 0.28 g/kg BW
Trial: 7666798
Drug: Alpha-ketoglutarate 0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-ketoglutarate 0.28 g/kg BW
Trial: 7666798
Drug: Control (glucose
RxNorm normalized name: INFINITY CONTROL (GLUCOSE) NORMAL CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (glucose 2 g/kg BW)
Trial: 30478972
Drug: Traditional speech
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional speech therapy (control group)
Trial: 27061732
Drug: Moderate stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate stress during preparation for a medical exam with high-salt intake
Trial: 25792627
Drug: Conventional hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional hormone therapy
Trial: 25792627
Drug: Ibandronate monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate monthly
Trial: 17058239
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg/6 h)
Trial: 17058239
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with steroids
Trial: 12629535
Drug: GTS‐21 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTS‐21 (25, 75 and 150 mg)
Trial: 10853877
Drug: Low-dose ATP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ATP infusion (25-40 microg kg(‐1) min(‐1))
Trial: 10853877
Drug: Middle-dose ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle-dose ATP infusion (45-60 microg kg(‐1) min(‐1))
Trial: 10853877
Drug: High-dose ATP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ATP infusion (65-75 microg kg(‐1) min(‐1))
Trial: 3839973
Drug: Sucralfate (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (6 g per day)
Trial: 3839973
Drug: Open sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open sucralfate treatment (after initial placebo)
Trial: 12810993
Drug: Cyclosporine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (3 mg/kg/day, increased to 4 mg/kg after two weeks if response was inadequate)
Trial: 12810993
Drug: Methotrexate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (0.5 mg/kg weekly)
Trial: 1862891
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac tromethamine (30 mg)
Trial: 6349780
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by adjuvant chemotherapy (5-FU and methyl-CCNU)
Trial: 31204040
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (IANB injection with 2% lidocaine)
Trial: 25730446
Drug: Medical honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical honey gel
Trial: 17402274
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg once daily for 8 weeks
Trial: 17402274
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg once daily for 8 weeks
Trial: 15613923
Drug: FoodState Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FoodState Vitamin C complex (500 mg vitamin C, 160 mg bioflavonoids, 600 mg magnesium and 900 mg vitamin B complex)
Trial: 9150780
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg.kg‐1
Trial: 9150780
Drug: Tramadol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.5 mg.kg‐1
Trial: 9150780
Drug: Tramadol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 0.5 mg.kg‐1, 1 mg.kg‐1, and 2 mg.kg‐1
Trial: 7715467
Drug: Estrogen-gestagen replacement
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-gestagen replacement therapy